Sordoni Golf Outing Raises $40,000 for the Linda E. Cardinale Multiple Sclerosis Center
October 13, 2022 11:30 ET | Sordoni Construction Co.
BEDMINSTER, N.J., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Sordoni Construction Co., a Bedminster-based construction management company, recently donated $40,000 to The Linda E. Cardinale Multiple...
Vantage Market Research.png
Multiple Sclerosis (MS) Drugs Market Size to Hit Sales of $31.2 Bn by 2028 | Biogen, Novartis, and Roche Hold Over 55% Share of Multiple Sclerosis Drugs
October 11, 2022 04:10 ET | Vantage Market Research
WASHINGTON, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Global multiple sclerosis drugs market size was $25.1 Billion in 2021 and is estimated to generate revenue of $31.2 Billion by 2028 at a CAGR of 3.7%...
AMR Logo.png
Global Neurological Biomarkers Market is Expected to Reach $18.9 Billion by 2031: Says AMR
September 27, 2022 12:00 ET | Allied Market Research
Portland, OR, Sept. 27, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global Neurological Biomarkers Market size was estimated at $5.4 billion...
U.S. Patent Office Issues Trethera Composition of Matter Patent Covering TRE-515, Extending Market Exclusivity to Late 2041
September 20, 2022 12:47 ET | Trethera Corporation
LOS ANGELES, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control and Improve Multiple Sclerosis Symptoms in Mouse Models
September 07, 2022 12:37 ET | Trethera Corporation
LOS ANGELES, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis
August 30, 2022 10:37 ET | Trethera Corporation
LOS ANGELES, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of...
Trethera Receives U.S. Patent Office Notice of Allowance Covering TRE-515 Structural Claims, Extending Protections to Late 2041
August 17, 2022 12:38 ET | Trethera Corporation
LOS ANGELES, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
clene-logo@2x.png
Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis
August 15, 2022 07:00 ET | Clene Inc.
CNM-Au8 met primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional Composite (mMSFC) compared to placebo over 48 weeks in the mITT...
Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 for the Treatment of Demyelinating Optic Neuritis
August 09, 2022 12:47 ET | Trethera Corporation
LOS ANGELES, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
NeurologyLive® Announces Giants of Multiple Sclerosis™ Inaugural Class of Inductees
June 03, 2022 09:56 ET | NeurologyLive®
CRANBURY, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- NeurologyLive® and the Consortium of Multiple Sclerosis Centers (CMSC) today announced the inaugural class of Giants of Multiple Sclerosis™...